Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.

Chen, Jiaxian; Qi, Lin; Tang, Yongxiang; Tang, Guyu; Gan, Yu; Cai, Yi

Chen, Jiaxian; Qi, Lin; Tang, Yongxiang; Tang, Guyu; Gan, Yu; Cai, Yi.

Afiliación

Chen J; Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Qi L; Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Tang Y; Department of PET Center, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Tang G; Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Gan Y; Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Cai Y; Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.

Front Cell Dev Biol ; 10: 958180, 2022.

Article en En | MEDLINE | ID: mdl-36036001

Palabras clave

castration-resistant prostate cancer; positron emission tomography; prostate-specific membrane antigen; radioligand therapy; theranostics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Cell Dev Biol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google